J&J Q2 FY26: Revenue +6.6% on oncology strength; biosimilar/generic headwinds intensify

Filed July 23, 2026 · Period ending June 28, 2026 · Compared to 10-Q Jul 24, 2025 · ~2 min read

Key Changes

• high

  Revenue grew 6.6% YoY to $25.3B, driven by TREMFYA (+70.6%), DARZALEX (+20.6%), and CARVYKTI (+55.1%) offsetting STELARA biosimilar erosion (now 5.0% drag on worldwide sales, 7.0% in U.S.).

  MD&A: Revenue Growth & Product Performance verify on EDGAR →
• high

  SIMPONI biosimilars launched in Europe Q2 2026 with U.S. entry expected later in 2026; OPSUMIT generics entered U.S. late Q2 2026; company warns of future sales reductions for both franchises.

  MD&A: Biosimilar & Generic Competition verify on EDGAR →
• high

  New supply chain restructuring program initiated in Innovative Medicine with $650-750M estimated costs through 2029; $200M recorded in Q2 2026, primarily asset impairments.

  Notes: Restructuring Programs verify on EDGAR →